About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Regeneron Pharmaceuticals, Inc. (REGN) is a Healthcare company in the Biotechnology industry with a market capitalisation of $80.5B. The stock trades at 19.34x trailing earnings and yields 0.48%.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $80.5B
- P/E ratio
- 19.34
- Forward P/E
- 12.89
- EPS (TTM)
- $40.40
- Revenue (TTM)
- $15.5B
- Free cash flow
- $3.1B
- Profit margin
- 27.9%
- Dividend yield
- 0.48%
- Beta
- 0.19
- Shares outstanding
- 101.1M
Financial health: Strong8.2/10
8 strengths, 1 concern. Weakest points: earnings growth.
- Debt to equity: 0.06 (Strong, benchmark < 0.5) — Debt of 0.06x equity is conservative against the 0.5x benchmark. It has improved over the last 4 years.
- Net debt vs cash flow: 0.0y (Strong, benchmark < 4 years) — Holds more cash than debt ($1.1B net cash).
- Current ratio: 4.13 (Strong, benchmark > 1.5) — Short-term assets cover 4.13x short-term liabilities, against Graham's 1.5x floor. It has deteriorated over the last 4 years.
- Return on equity: 14.0% (Watch, benchmark > 15%) — Earns 14.0% on shareholder equity, short of the > 15% mark.
- Gross margin: 44.5% (Strong, benchmark > 40%) — Keeps 44.5% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 27.9% (Strong, benchmark > 10%) — Turns 27.9% of revenue into profit, comfortably past the > 10% mark.
- Free cash flow: $4.1B (Strong, benchmark positive) — Generated $4.1B of free cash flow after capital spending. It has been broadly flat over the last 4 years.
- Revenue growth: 16.7% (Strong, benchmark > 10%) — Revenue changed 16.7% year on year, comfortably past the > 10% mark.
- Earnings growth: -4.5% (Concern, benchmark > 10%) — Earnings changed -4.5% year on year, well short of the > 10% mark.
- PEG ratio: 1.29 (Watch, benchmark < 1) — At 1.29, the price looks fair relative to expected growth — Lynch treated 1.0 as fair value.
- Payout ratio: 9.0% (Strong, benchmark < 60%) — Pays out 9.0% of earnings as dividends, leaving room to keep paying.